HCA Healthcare, Inc. Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. HCA Healthcare, Inc. operates 192 hospitals, 125 freestanding surgery centers, and 26 freestanding endoscopy centers across 20 U.S. states and England. The company is organized into three geographic groups: National, Atlantic, and American.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $18,321 million | $17,339 million |
| Net Income (Attributable to HCA) | $1,610 million | $1,591 million |
| Diluted EPS | $6.45 | $5.93 |
| Operating Cash Flow | $1,651 million | $2,469 million |
| Total Debt | $44,576 million | $43,031 million |
| Cash and Equivalents | $1,060 million | $1,284 million |
| Adjusted Segment EBITDA | $4,012 million | $3,624 million |
Margins: Net income attributable to HCA represented 8.8% of revenues in Q1 2025, compared to 9.2% in Q1 2024. Salaries and benefits were 43.6% of revenues.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5.7% year-over-year, driven by a 3.1% increase in equivalent admissions and a 2.5% increase in revenue per equivalent admission.
- Volume Trends: Consolidated admissions rose 2.8%. Inpatient surgical volumes increased 0.3%, while outpatient surgical volumes declined 2.5%. Emergency department visits increased 3.7%.
- Profitability: Net income attributable to HCA increased 1.2% to $1.610 billion. This growth occurred despite a significant reduction in non-recurring gains; Q1 2024 included a $201 million gain on the sale of a California hospital, whereas Q1 2025 included only a $1 million gain.
- Cash Flow: Operating cash flow declined $818 million to $1.651 billion, primarily due to a $1.157 billion negative impact from changes in working capital (specifically accounts receivable and payables).
- Debt Structure: Total debt increased to $44.6 billion. In February 2025, the company repaid $2.6 billion in maturing notes and issued $5.25 billion in new senior notes with maturities ranging from 2028 to 2055. The company also entered an $8.0 billion senior unsecured revolving credit facility.
Guidance, Outlook, and Risks
- Capital Expenditures: Planned capital expenditures for 2025 are expected to approximate between $5.0 billion and $5.2 billion.
- Share Repurchases: The company repurchased 7.76 million shares in Q1 2025 at an average price of $322.84. Approximately $8.26 billion remains available under the current authorization.
- Dividends: A quarterly dividend of $0.72 per share was declared on April 24, 2025, payable June 30, 2025.
- Risks and Contingencies:
- Regulatory: Significant exposure to changes in Medicare and Medicaid reimbursement rates and potential expiration of enhanced premium tax credits in 2025.
- Legal: Ongoing IRS examinations of 2022 and 2023 tax returns; potential for material adverse effects from litigation and False Claims Act investigations.
- Debt: High indebtedness levels ($44.6 billion) create vulnerability to interest rate fluctuations and economic downturns.
Investor Verification Checklist
- Working Capital Dynamics: Verify the sustainability of the $1.157 billion negative working capital impact on operating cash flow and its effect on liquidity.
- Debt Refinancing Terms: Review the specific interest rates and covenants of the new $5.25 billion senior notes issued in February 2025.
- Uncompensated Care Costs: Monitor the estimated cost of total uncompensated care, which rose to $1.055 billion in Q1 2025.
- Outpatient Volume: Assess the cause and potential duration of the 2.5% decline in outpatient surgical volumes.
- Tax Rate Volatility: Confirm the effective tax rate of 23.8% and the impact of reduced deductible share-based compensation.